Patents Assigned to LivaNova USA, Inc.
-
Patent number: 10632306Abstract: Devices, systems and methods of neurostimulation for treating obstructive sleep apnea.Type: GrantFiled: August 25, 2017Date of Patent: April 28, 2020Assignee: LivaNova USA, Inc.Inventors: Stephen L. Bolea, Thomas B. Hoegh, Brian D. Kuhnley, Dale G. Suilmann, Bruce J. Persson, John P. Beck, Sidney Hauschild, Paula M. Kaplan, Adam K. Hoyhtya, Wondimeneh Tesfayesus, Robert E. Atkinson, Peter R. Eastwood, David R. Hillman
-
Patent number: 10632308Abstract: A method including chronically implanting a nerve cuff electrode on a portion of a hypoglossal nerve, chronically implanting a respiration sensing lead subcutaneously in a thorax of a patient, the respiration sensing lead having a plurality of bio-impedance electrodes defining at least one bio-impedance vector. The method may also include sensing a bio-impedance signal corresponding to respiration via a bio-impedance vector on an anterior side of the thorax, analyzing the bio-impedance signal to identify onsets of expiration, predicting an onset of a future expiratory phase, and delivering a stimulus to the portion of the hypoglossal nerve via the nerve cuff electrode, wherein the stimulus is delivered as a function of the bio-impedance signal; wherein stimulus delivery is initiated before the onset of the future expiratory phase and continued during an entire inspiratory phase, and wherein the method is performed without identifying an onset of an inspiratory phase.Type: GrantFiled: July 31, 2017Date of Patent: April 28, 2020Assignee: LivaNova USA, Inc.Inventors: Stephen L. Bolea, Thomas B. Hoegh, Bruce J. Persson, Robert E. Atkinson, Scott T. Mazar
-
Publication number: 20200113473Abstract: Medical device systems and methods for operating medical device systems conserve energy by efficiently managing computational demands of the systems. A first analysis, having relatively lower computational processing demand than at least a second analysis, processes signals from a subject to determine a first estimate of a propensity for the subject to have a neurological event. If the first estimate meets a set of specified criteria, a second analysis is performed to determine a second estimate of the propensity for the subject to have a neurological event.Type: ApplicationFiled: November 1, 2019Publication date: April 16, 2020Applicant: LivaNova USA, Inc.Inventor: Kent Leyde
-
Publication number: 20200113446Abstract: Methods, systems, and apparatuses for detecting seizure events are disclosed, including a system for identification of an increased risk of a severe neurological event. The system may include an electroencephalogram (“EEG”) monitoring unit configured to collect EEG data from the patient during at least a postictal phase or one or more seizures and a processing unit configured to receive the EEG data from the EEG monitoring unit. The processing unit is configured to detect postictal EEG suppression from the EEG data and to identify the increased risk of the severe neurological event based on the detected postictal EEG suppression. Other embodiments are described and claimed.Type: ApplicationFiled: October 18, 2019Publication date: April 16, 2020Applicant: LivaNova USA, Inc.Inventor: Shivkumar SABESAN
-
Publication number: 20200108256Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. Between titration sessions one or more parameters, such as, for example, an acclimation interval, may be adjusted based on the patient's response to the stimulation. This personalized titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: ApplicationFiled: December 5, 2019Publication date: April 9, 2020Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. KenKnight, Badri Amurthur, Scott R. Stubbs
-
Patent number: 10500398Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. Between titration sessions one or more parameters, such as, for example, an acclimation interval, may be adjusted based on the patient's response to the stimulation. This personalized titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: GrantFiled: November 23, 2016Date of Patent: December 10, 2019Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. KenKnight, Badri Amurthur, Scott R. Stubbs
-
Publication number: 20190344082Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. This neural fulcrum zone corresponds to a combination of stimulation parameters at which autonomic engagement is achieved, while the tachycardia-inducing stimulation effects are offset by the bradycardia-inducing effects, thereby minimizing side effects such as significant heart rate changes while providing a therapeutic level of stimulation.Type: ApplicationFiled: May 24, 2019Publication date: November 14, 2019Applicants: LivaNova USA, Inc., EAST TENNESSEE STATE UNIVERSITYInventors: Bruce H. KenKnight, Jeffrey L. Ardell, Imad Libbus, Badri Amurthur
-
Patent number: 10463859Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. This neural fulcrum zone may be identified by monitoring a patient's response to incrementally increased intensity settings at a first frequency. If the incremental intensity increases do not result in the identification of the neural fulcrum zone, the frequency may be changed to provide finer resolution identification of the neural fulcrum zone.Type: GrantFiled: May 3, 2017Date of Patent: November 5, 2019Assignees: LivaNova USA, Inc., East Tennessee State UniversityInventors: Bruce H. KenKnight, Imad Libbus, Badri Amurthur, Jeffrey L. Ardell
-
Patent number: 10463270Abstract: Medical device systems and methods for operating medical device systems conserve energy by efficiently managing computational demands of the systems. A first analysis, having relatively lower computational processing demand than at least a second analysis, processes signals from a subject to determine a first estimate of a propensity for the subject to have a neurological event. If the first estimate meets a set of specified criteria, a second analysis is performed to determine a second estimate of the propensity for the subject to have a neurological event.Type: GrantFiled: November 30, 2015Date of Patent: November 5, 2019Assignee: LivaNova USA, Inc.Inventor: Kent Leyde
-
Patent number: 10448839Abstract: Methods, systems, and apparatuses for detecting seizure events are disclosed, including a system for identification of an increased risk of a severe neurological event. The system may include an electroencephalogram (“EEG”) monitoring unit configured to collect EEG data from the patient during at least a postictal phase of one or more seizures and a processing unit configured to receive the EEG data from the EEG monitoring unit. The processing unit is configured to detect postictal EEG suppression from the EEG data and to identify the increased risk of the severe neurological event based on the detected postictal EEG suppression. Other embodiments are described and claimed.Type: GrantFiled: April 23, 2012Date of Patent: October 22, 2019Assignee: LivaNova USA, Inc.Inventor: Shivkumar Sabesan
-
Patent number: 10449363Abstract: A patient suffering from congestive heart failure is at increased risk of cardiac arrhythmogenesis during sleep, particularly if experiencing central sleep apnea as a co-morbidity. Low intensity peripheral neurostimulation therapies that target imbalance of the autonomic nervous system have been shown to improve clinical outcomes. Thus, bi-directional autonomic regulation therapy is delivered to the cervical vagus nerve at an intensity that is insufficient to elicit pathological or acute physiological side effects and without the requirement of an enabling physiological feature or triggering physiological marker. The patient's physiology is monitored to identify periods of sleep. In one embodiment, upon sensing a condition indicative of tachyarrhythmia following a period of bradycardia, as naturally occurs during sleep, an enhanced “boost” dose of bi-directional neural stimulation intended to “break” the tachyarrhythmic condition is delivered.Type: GrantFiled: May 3, 2017Date of Patent: October 22, 2019Assignee: LivaNova USA, IncInventors: Imad Libbus, Badri Amurthur, Bruce H. Kenknight
-
Patent number: 10426961Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A computer-implemented control system is operated to automatically identify a neural fulcrum zone based on a monitored patient physiological response. Ongoing neurostimulation therapy is delivered within the neural fulcrum zone.Type: GrantFiled: April 20, 2018Date of Patent: October 1, 2019Assignees: LivaNova USA, Inc., East Tennessee State UniversityInventors: Imad Libbus, Badri Amurthur, Bruce H. KenKnight, Jeffrey L. Ardell
-
Patent number: 10426514Abstract: A self-dilating cannula for introduction into a patient's vasculature includes an elongate body and an atraumatic tip. The elongate body has a proximal end, a distal end, and a fluid-flow lumen extending therebetween. The atraumatic tip is positioned at the elongate body's distal end and has a blunted end and a conical shape. The atraumatic tip includes a plurality of fluid-flow openings proximal to the blunted nose that are configured to disperse fluid from the fluid-flow lumen in a plurality of directions with respect to the atraumatic tip. The atraumatic tip also includes an opening in the blunted nose that is sized to a guidewire.Type: GrantFiled: April 19, 2016Date of Patent: October 1, 2019Assignee: LivaNova USA, Inc.Inventors: Tamer Ibrahim, Jeffrey P. Sites
-
Publication number: 20190290901Abstract: An implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction is provided. A stimulation therapy lead includes helical electrodes configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins electrically connected to the helical electrodes. A neurostimulator includes an electrical receptacle into which the connector pins are securely and electrically coupled. The neurostimulator also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes in alternating cycles of stimuli application and stimuli inhibition that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials.Type: ApplicationFiled: January 25, 2019Publication date: September 26, 2019Applicant: LivaNova USA, Inc.Inventors: Imad LIBBUS, Badri AMURTHUR, Bruce H. KENKNIGHT
-
Patent number: 10413732Abstract: An implantable neurostimulator-implemented method for managing tachyarrhythmias upon a patient's awakening from sleep through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator, is configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers comprising the cervical vagus nerve of a patient. Operating modes of the pulse generator are stored. An enhanced dose of the electrical therapeutic stimulation is parametrically defined and tuned to prevent initiation of or disrupt tachyarrhythmia upon the patient's awakening from a sleep state through at least one of continuously-cycling, intermittent and periodic ON-OFF cycles of electrical pulses. Other operating modes, including a maintenance dose and a restorative dose are defined.Type: GrantFiled: June 22, 2018Date of Patent: September 17, 2019Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Badri Amurthur, Bruce H. KenKnight
-
Publication number: 20190274587Abstract: Devices and methods for treating obstructive sleep apnea by first performing an assessment of the patient that involves observing the patient's upper airway during a tongue protrusion maneuver. The assessment may, for example, be done using endoscopy to observe the upper airway while the patient is awake in the supine position. An adequate response of the upper airway during the tongue protrusion maneuver is indicative of likely therapeutic success with hypoglossal nerve stimulation, and may be used for making clinical decisions. The principles of the present invention may be applied to other therapeutic interventions for OSA involving the upper airway.Type: ApplicationFiled: March 15, 2019Publication date: September 12, 2019Applicant: LivaNova USA, Inc.Inventors: Wondimeneh TESFAYESUS, Stephen L. BOLEA, Peter R. EASTWOOD, David R. HILLMAN
-
Patent number: 10406363Abstract: A method of detecting an improvement in a seizure condition of a patient includes identifying a first EEG synchronization of the seizure condition of the patient; applying a therapy configured to improve the seizure condition of the patient; and identifying a second EEG synchronization of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced EEG synchronization of the patient such that the second EEG synchronization is less than the first EEG synchronization.Type: GrantFiled: April 20, 2016Date of Patent: September 10, 2019Assignee: LivaNova USA, Inc.Inventor: Shivkumar Sabesan
-
Publication number: 20190262615Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. This titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: ApplicationFiled: March 1, 2019Publication date: August 29, 2019Applicant: LivaNova USA, Inc.Inventors: Imad LIBBUS, Bruce H. KENKNIGHT, Badri AMURTHUR
-
Publication number: 20190255330Abstract: A method of detecting an improvement in a seizure condition of a patient includes identifying a first EEG synchronization of the seizure condition of the patient; applying a therapy configured to improve the seizure condition of the patient; and identifying a second EEG synchronization of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced EEG synchronization of the patient such that the second EEG synchronization is less than the first EEG synchronization.Type: ApplicationFiled: May 1, 2019Publication date: August 22, 2019Applicant: LivaNova USA, Inc.Inventor: Shivkumar SABESAN
-
Patent number: 10384065Abstract: An implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers including a patient's cervical vagus nerve. An operating mode is stored in the pulse generator. An enhanced dose of the electrical therapeutic stimulation is parametrically defined and tuned to prevent or disrupt tachyarrhythmia through continuously-cycling, intermittent and periodic electrical pulses. The patient's physiological state is monitored during physical exercise via at least one sensor included in the implantable neurostimulator, and upon sensing a condition indicative of cessation of the physical exercise, the enhanced dose is delivered for a period of time the enhanced dose to the vagus nerve.Type: GrantFiled: May 3, 2017Date of Patent: August 20, 2019Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Badri Amurthur, Bruce H. Kenknight